Resistance-free SARS-CoV-2 neutralizing drug development with high-affinity modified ACE2 protein.
- Funded by Japan Agency for Medical Research and Development (AMED)
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19Start & end year
20202020Funder
Japan Agency for Medical Research and Development (AMED)Principal Investigator
Assistant Professor Atsushi HOSHINOResearch Location
JapanLead Research Institution
Department of Cardiovascular medicine, Kyoto Prefectural University of MedicineResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
Pre-clinical studies
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable